205 related articles for article (PubMed ID: 34134948)
1. [Relapse of ankylosing spondylitis and its predictors after withdrawal of tumor necrosis factor-α inhibitors: a 52-week follow-up study].
Tang C; Chen F; Zheng S; Wu L; Chen S; Zhu J; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2021 May; 41(5):633-639. PubMed ID: 34134948
[TBL] [Abstract][Full Text] [Related]
2. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
3. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
van Weely SF; Kneepkens EL; Nurmohamed MT; Dekker J; van der Horst-Bruinsma IE
Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
[TBL] [Abstract][Full Text] [Related]
4. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
5. Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn.
Park JH; Kwon OC; Park MC
Clin Rheumatol; 2020 Dec; 39(12):3669-3675. PubMed ID: 32447601
[TBL] [Abstract][Full Text] [Related]
6. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
Kim Y; Park S; Kim HS
Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
Wang R; Dasgupta A; Ward MM
J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
[TBL] [Abstract][Full Text] [Related]
8. Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.
Jeong H; Eun YH; Kim IY; Kim H; Ahn JK; Lee J; Koh EM; Cha HS
Korean J Intern Med; 2018 Mar; 33(2):407-416. PubMed ID: 27729625
[TBL] [Abstract][Full Text] [Related]
9. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
10. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
Hebeisen M; Neuenschwander R; Scherer A; Exer P; Weber U; Tamborrini G; Micheroli R; Wildi LM; Zufferey P; Nissen MJ; Villiger PM; Bernhard J; Finckh A; van der Horst-Bruinsma IE; Sieper J; Landewé R; van der Heijde D; Ciurea A;
J Rheumatol; 2018 Apr; 45(4):506-512. PubMed ID: 29449504
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.
Fong W; Holroyd C; Davidson B; Armstrong R; Harvey N; Dennison E; Cooper C; Edwards CJ
Rheumatology (Oxford); 2016 Oct; 55(10):1837-42. PubMed ID: 27354684
[TBL] [Abstract][Full Text] [Related]
14. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
15. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
[TBL] [Abstract][Full Text] [Related]
16. Predictive Values of Blood Type I and Type II Interferon Production for Disease Activity and Clinical Response to TNF-α Blocking Therapy in Patients with Ankylosing Spondylitis.
Hu Y; Lou B; Jiang Z; Yu C
Tohoku J Exp Med; 2023 Jul; 260(3):263-271. PubMed ID: 37081619
[TBL] [Abstract][Full Text] [Related]
17. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis.
Wang R; Dasgupta A; Ward MM
JAMA Netw Open; 2022 Mar; 5(3):e222312. PubMed ID: 35289857
[TBL] [Abstract][Full Text] [Related]
18. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
19. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry.
Glintborg B; Højgaard P; Lund Hetland M; Steen Krogh N; Kollerup G; Jensen J; Chrysidis S; Jensen Hansen IM; Holland-Fischer M; Højland Hansen T; Nilsson C; Espesen J; Nordin H; Rasmussen Loft AG; Pelck R; Lorenzen T; Flejsborg Oeftiger S; Unger B; Jaeger F; Mosborg Petersen P; Rasmussen C; Dreyer L
Rheumatology (Oxford); 2016 Apr; 55(4):659-68. PubMed ID: 26628579
[TBL] [Abstract][Full Text] [Related]
20. The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis.
Tuğsal HY; Artin GK; Can G; Çapar S; Zengin B; Akar S; Dalkiliç HE; Şenel AS; Koca SS; Göker B; Yazici A; İnanç GN; Ellidokuz H; Akkoç N; Önen F
Turk J Med Sci; 2023 Aug; 53(4):970-978. PubMed ID: 38031953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
